HCPCS Code Q9966: Low Osmolar Contrast Material Billing Guide

Key Takeaways

HCPCS Code Q9966 describes low osmolar contrast material with 200-299 mg/mL iodine concentration, billed per mL administered

Units equal the exact number of milliliters given – a 50 mL injection is billed as 50 units

Reimbursement status under OPPS varies by setting and year; verify packaging rules in the current CMS OPPS addendum before billing

Pabau’s claims management software supports accurate HCPCS unit tracking and modifier attachment to reduce contrast material denials

Contrast material claims are among the most frequently denied line items in outpatient radiology billing. HCPCS Code Q9966 is the code coders reach for when a patient receives low osmolar contrast material at an iodine concentration between 200 and 299 mg/mL – but knowing the code number is only half the job. Units calculated incorrectly, modifiers omitted, or reimbursement assumptions made without checking the current year’s OPPS rules are the three patterns that generate the most avoidable write-offs on contrast charges.

This reference covers everything billing staff and coders need: the official descriptor for HCPCS Code Q9966, how to count units correctly, which modifiers apply in which scenarios, how Medicare and OPPS handle reimbursement, the related Q-code family (Q9965, Q9967, Q9968), and an NDC crosswalk for common contrast agents including Isovue-200 and Omnipaque 240.

HCPCS Code Q9966: Definition and Code Classification

HCPCS Code Q9966 has the following official descriptor: Low osmolar contrast material, 200-299 mg/mL iodine concentration, per mL. The “per mL” portion is not decoration – it determines how units are calculated on every claim.

The code sits within HCPCS Level II as a temporary Q-code under the Contrast Agents/Diagnostic Imaging category (Q9950-Q9983), maintained by the Centers for Medicare and Medicaid Services (CMS). Q-codes are temporary codes assigned by CMS for Medicare administrative purposes; they are distinct from the permanent CPT code set maintained by the AMA. This classification determines how the code is updated and which payers recognize it.

Low osmolar contrast material (LOCM) is iodinated contrast used during CT scans, angiography, myelography, and intravenous urography. Compared to high osmolar contrast material (HOCM), LOCM carries a lower risk of adverse reactions, making it the standard choice in most outpatient imaging settings. The 200-299 mg/mL iodine concentration range covered by Q9966 represents the lower end of clinically used LOCM concentrations – appropriate for certain CT protocols and fluoroscopic procedures where a less dense contrast column is sufficient.

Per CMS’s 2017 HCPCS Application Summary, Q9966 adequately describes Optiray 240 (ioversol) and is available for assignment by insurers where appropriate. Isovue-200 (iopamidol) and Omnipaque 240 (iohexol) are also commonly reported under this code. The iodine concentration of the specific product used – not the volume drawn or the product name – determines which Q-code applies. Coders should confirm the mg/mL concentration documented in the procedure note before assigning Q9966.

Units and Billing Guidelines for HCPCS Code Q9966

The unit calculation rule for Q9966 is straightforward but frequently applied incorrectly. Because the descriptor says “per mL,” the number of units billed equals the number of milliliters actually administered to the patient – not the number of vials drawn, not the total volume in the syringe, and not a fixed per-procedure unit.

If a CT abdomen and pelvis requires 80 mL of Omnipaque 240, the correct billing is Q9966 with 80 units. If a fluoroscopy procedure uses 0.5 mL of Omnipaque 240, the unit is 0.5 (some payers round to whole numbers; confirm payer-specific rules before rounding). The operative or procedure report must document the exact volume administered. Without that documentation, the claim lacks the support needed to survive a pre-payment review or audit.

Two additional documentation requirements apply in most settings. First, the National Drug Code (NDC) for the specific contrast agent used should be reported alongside Q9966 – many payers and Medicare contractors require NDC reporting for drug-related HCPCS codes. Second, the route of administration must be clear from the clinical note. Accurate claims management requires the charge capture workflow to pull the administered volume directly from the clinical record rather than relying on staff memory or vial-level estimates.

NDC Crosswalk for Common Contrast Agents Reported Under Q9966

The following contrast agents fall within the 200-299 mg/mL iodine concentration range and are commonly billed using HCPCS Code Q9966:

Always verify the NDC for the specific lot in use at your facility. NDC numbers vary by package size and concentration formulation. The product label is the authoritative source; the NDC listed in your pharmacy dispensing system is the one that goes on the claim.

Medicare Reimbursement and OPPS Coverage for HCPCS Code Q9966

Reimbursement for HCPCS Code Q9966 is setting-dependent and changes annually based on CMS rulemaking. The most common source of billing errors is assuming the prior year’s payment rules still apply. Before billing contrast codes in any new calendar year, verify the current OPPS addendum for Q9966’s packaging status.

Hospital outpatient department (HOPD) / OPPS setting: Under the Outpatient Prospective Payment System, contrast media payment is tied to whether the code is classified as separately payable or packaged into the Ambulatory Payment Classification (APC) for the associated imaging procedure. Pass-through payment status for Q9966 has expired per available source data – this time-limited status provided higher payments during the transitional period. Whether contrast remains separately payable under current OPPS rules or is packaged into the imaging APC should be confirmed against the CMS Physician Fee Schedule and OPPS addendum for the current year. One analysis notes that contrast may remain separately payable for certain CT and angiography procedures because its cost is not fully reflected in the base APC rate, but this varies by procedure type and year.

Physician office / non-facility setting: In the physician office, contrast is typically billed separately under the buy-and-bill model. The practice purchases the contrast agent, administers it, and bills Medicare at the applicable fee schedule rate – generally structured around Average Sales Price (ASP) plus a percentage markup. Verify the current ASP-based payment limit for Q9966 in the applicable fee schedule before setting your charge master amount.

Ambulatory Surgical Center (ASC): Contrast material is generally not separately payable in the ASC setting under current CMS policy – it is packaged into the facility payment for the procedure. Confirm ASC-specific packaging rules with your MAC before billing Q9966 separately in this setting.

Commercial payers: Do not assume commercial payers follow Medicare OPPS rules. UHC Oxford’s Radiopharmaceuticals and Contrast Media policy, for example, lists Q9966 explicitly and has specific coverage criteria. Verify each payer’s current policy before billing. A compliant billing workflow includes payer-specific coverage verification as a standard pre-claim step for contrast charges.

Applicable Modifiers for HCPCS Code Q9966

Modifier selection for contrast material claims requires precision. Applying the wrong modifier – or omitting a required one – is a primary trigger for claim denials and compliance flags. The following modifiers are relevant to Q9966 billing:

The X-modifiers (XE, XP, XS, XU) are preferred over the general modifier 59 when they apply, because they provide greater specificity and reduce the risk of triggering an audit. Use modifier 59 only when none of the X-modifier definitions fit the clinical scenario. For radiology billing, modifier JA is particularly important when payers require route-of-administration reporting on drug HCPCS codes.

Modifier JW (drug wastage) deserves special attention. CMS and most commercial payers require that the amount wasted be documented in the clinical record at the time of service. Retroactive documentation is not acceptable. The claim should show two line items: one for the amount administered (Q9966 with administered mL units) and one for the amount wasted (Q9966 with wasted mL units, modifier JW). Some payers have eliminated separate JW reimbursement for low-cost drugs – confirm your payer’s current JW policy before billing.

Reduce Contrast Claim Denials with Smarter Billing Workflows

Pabau's claims management tools help radiology and outpatient imaging teams capture administered volumes, attach modifiers accurately, and track HCPCS billing compliance across every procedure. See how it works for your facility.

Book a demo

Q9965, Q9966, Q9967, and Q9968: Comparison of Related HCPCS Codes

The Q9965-Q9968 code family covers the full iodine concentration range for low osmolar and related contrast agents. Assigning the wrong code within this family – typically because the concentration was not verified from the product label – is a common documentation-related denial reason. The table below compares these codes side by side.

Q9967 (300-399 mg/mL) is the code most often confused with Q9966. Both cover LOCM, but the concentration boundary at 300 mg/mL is where most coding errors occur. When Omnipaque 300 or Isovue-300 is documented in the procedure note, Q9967 applies – not Q9966. When Omnipaque 240 or Isovue-200 is documented, Q9966 applies. The coder must read the product name and confirm the iodine concentration before code assignment.

Q9968 is categorically different – it covers non-radioactive, non-contrast visualization adjuncts such as Methylene Blue and Isosulfan Blue used during sentinel lymph node procedures. It should never be confused with the LOCM codes. For broader radiology and imaging billing compliance, Pabau’s lab management tools can support consistent charge capture documentation across contrast-dependent procedures.

Common Denial Reasons and Documentation Requirements

Contrast material claims under HCPCS Code Q9966 fail for predictable reasons. Understanding these patterns makes it possible to build denial prevention into the workflow rather than managing appeals after the fact.

• Incorrect units: Billing one unit regardless of volume administered is the most frequent error. The claim must reflect actual mL given as documented in the procedure note.
• Missing NDC: Many Medicare Administrative Contractors (MACs) and commercial payers require an 11-digit NDC on the claim for drug-related HCPCS codes. Omitting it generates a claim-level rejection before adjudication even begins.
• Wrong concentration code: Confirming that 240 mg/mL falls within the 200-299 mg/mL range (Q9966) and not the 300-399 mg/mL range (Q9967) is a documentation step, not a math problem. Read the label.
• Bundling under OPPS: Some MAC and OPPS edits package contrast into the imaging APC for the current year. Submitting Q9966 as a separate line item when it is packaged results in a denial or automatic zero payment.
• Modifier JW documentation gap: Waste reporting without same-day clinical documentation is retroactive and not supportable on audit. Document wasted volume at the time of the procedure.
• Payer policy mismatch: Assuming all payers follow Medicare rules leads to denials from commercial carriers with independent coverage policies. Verify payer-by-payer before billing.

For facilities managing high contrast volumes across multiple imaging suites, a standardized charge capture process tied to the clinical record reduces all six of these failure types. Integrating billing workflows with structured clinical documentation ensures that the administered volume, product NDC, and route of administration are captured at the point of care rather than reconstructed during billing.

Expert Picks: Related Billing Resources

Expert Picks

Need a structured claims management workflow? Pabau Claims Management Software supports accurate HCPCS code submission, modifier tracking, and denial management for outpatient billing teams.

Billing contrast alongside fluoroscopy? Procedure Code Billing Reference covers documentation requirements for concurrent procedure and supply code submissions.

Managing compliance across imaging services? HIPAA Compliance for Medical Offices outlines documentation and retention requirements relevant to radiology and outpatient facility billing.

Looking up the official HCPCS code set? AAPC Codify HCPCS Lookup provides a searchable HCPCS Level II code database for quick code verification and crosswalk reference.

Conclusion

Contrast material billing generates avoidable write-offs when unit calculation, modifier selection, and payer-specific reimbursement rules are not handled systematically. HCPCS Code Q9966 is straightforward in its descriptor – per mL, 200-299 mg/mL iodine concentration – but the billing environment around it changes annually with CMS rulemaking and varies across payers.

Verify the current OPPS packaging status for Q9966 before billing each new year. Document administered volumes at the point of care, not during billing. Match modifier selection to the specific clinical scenario. For facilities looking to reduce contrast claim denials systematically, Pabau’s claims management tools link charge capture to clinical documentation so the right units, NDC, and modifier reach the claim every time. Book a demo to see how Pabau handles HCPCS billing workflows for imaging and outpatient settings.

Frequently Asked Questions